Literature DB >> 17339511

Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment.

Charles W LeBaron1, Judith Beeler, Bradley J Sullivan, Bagher Forghani, Daoling Bi, Carol Beck, Susette Audet, Paul Gargiullo.   

Abstract

OBJECTIVE: To evaluate the persistence of measles antibodies after 2 doses of measles vaccine in a setting where exposure to wild-type measles was unlikely. Measles was declared eliminated from the United States in 2000, an achievement attributed to effective implementation of a routine 2-dose vaccination policy. Some have questioned whether measles transmission could resume if immunity wanes in the absence of boosting from wild-type measles.
DESIGN: Prospective, observational, volunteer cohort study.
SETTING: Rural Wisconsin health maintenance organization. PARTICIPANTS: Children who received the second measles vaccine dose at kindergarten (aged 4-6 years) or middle school (aged 10-12 years) in 1994 or 1995. Serum samples were collected periodically during a 10-year period for the kindergarten group and a 5-year period for the middle school group. INTERVENTION: Second dose of measles vaccine. MAIN OUTCOME MEASURE: Measles antibody levels were assessed by plaque-reduction neutralization: titers less than 8 mIU/mL were considered seronegative and suggestive of susceptibility to measles, and titers of 120 mIU/mL or less were considered low and suggestive of potential susceptibility.
RESULTS: During the study period, no measles was reported in the study area. Voluntary attrition reduced the study population from 621 at enrollment to 364 (58.6%) by study end. Before the second dose, 3.1% (19/621) had low titers, of whom 74% (14/19) were antibody-negative, with geometric mean titers being significantly higher in kindergarteners (1559 mIU/mL) than in middle schoolers (757 mIU/mL) and rates of negativity significantly lower (1.0% [3/312] vs 3.6% [11/309]). One month after the second dose, 0.2% (1/612) had low titers and none was seronegative, with geometric mean titers being significantly higher in kindergarteners (2814 mIU/mL) than in middle schoolers (1672 mIU/mL). By study end, 4.9% (18/364) had low titers and none was seronegative, with no significant difference in geometric mean titers between kindergarteners (641 mIU/mL) and middle schoolers (737 mIU/mL) when both groups were aged 15 years. Projections suggest that the proportion of persons with low antibody levels may increase over time.
CONCLUSIONS: Measles antibody persisted in all vaccinees available for follow-up 10 years after a second dose of vaccine, with no seronegative results detected. Declining titers suggest the need for vigilance in ensuring disease protection for the vaccinated population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339511     DOI: 10.1001/archpedi.161.3.294

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  24 in total

1.  Humoral and cellular immune responses to measles and tetanus: the importance of elapsed time since last exposure and the nature of the antigen.

Authors:  Patricia O Viana; Erika Ono; Maristela Miyamoto; Reinaldo Salomao; Beatriz T Costa-Carvalho; Lily Y Weckx; Maria Isabel de Moraes-Pinto
Journal:  J Clin Immunol       Date:  2010-04-20       Impact factor: 8.317

2.  The Reemergence of Measles.

Authors:  C L Abad; N Safdar
Journal:  Curr Infect Dis Rep       Date:  2015-12       Impact factor: 3.725

3.  In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence.

Authors:  T N Figueira; L M Palermo; A S Veiga; D Huey; C A Alabi; N C Santos; J C Welsch; C Mathieu; B Horvat; S Niewiesk; A Moscona; M A R B Castanho; M Porotto
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

4.  Performance Characteristics of a Multiplex Flow Immunoassay for Detection of IgG-Class Antibodies to Measles, Mumps, Rubella, and Varicella-Zoster Viruses in Presumptively Immune Health Care Workers.

Authors:  Elitza S Theel; Marisa Sorenson; Crystal Rahman; Dane Granger; Andrew Vaughn; Laura Breeher
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

5.  Outbreak of measles among persons with secondary vaccine failure, China, 2018.

Authors:  Zhujiazi Zhang; Meng Chen; Rui Ma; Jingbin Pan; Luodan Suo; Li Lu
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

6.  Maternal mumps antibodies in a cohort of children up to the age of 1 year.

Authors:  E Leuridan; N Goeyvaerts; N Hens; V Hutse; P Van Damme
Journal:  Eur J Pediatr       Date:  2012-03-07       Impact factor: 3.183

7.  Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; Krista M Goergen; Diane E Grill; Min-Hsin Chen; Lijuan Hao; Joseph Icenogle; Gregory A Poland
Journal:  Vaccine       Date:  2019-11-12       Impact factor: 3.641

8.  A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Megan O'Byrne; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2011-05-01       Impact factor: 3.641

9.  Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.

Authors:  Amy Parker Fiebelkorn; Laura A Coleman; Edward A Belongia; Sandra K Freeman; Daphne York; Daoling Bi; Ashwin Kulkarni; Susette Audet; Sara Mercader; Marcia McGrew; Carole J Hickman; William J Bellini; Rupak Shivakoti; Diane E Griffin; Judith Beeler
Journal:  J Infect Dis       Date:  2015-11-23       Impact factor: 5.226

Review 10.  Variability in Humoral Immunity to Measles Vaccine: New Developments.

Authors:  Iana H Haralambieva; Richard B Kennedy; Inna G Ovsyannikova; Jennifer A Whitaker; Gregory A Poland
Journal:  Trends Mol Med       Date:  2015-11-18       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.